drugset / Trial / NCT03201796

Prulifloxacin in Chronic Bacterial Prostatitis (CBP)

NCT03201796

Phase 2 Completed 168 enrolled Angelini Pharma Hippocrates Research · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to levofloxacin in the treatment of patients affected by CBP.

Timeline

Start
2016-02-02
Primary completion
2020-05-19
Completion
2020-05-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levofloxacin Small molecule 500 mg Oral
Subject Prulifloxacin Small molecule 600 mg Oral

Indications